TruTechnologies, makers of TruLab

FDA’s new real-time clinical data review pilot points to an important shift in drug development: reducing the delay between trial data generation and regulatory review. But as Dr. Richard Graham notes in Pharmaceutical Executive, much of this initiative appears focused on the back end of the process — helping FDA see aggregated data signals sooner as trials progress. That matters. But it also raises a deeper question: what happens before the data reaches that review layer? If sponsors want faster decisions, they also need earlier confidence in how the data was generated at the site level. Real-time review is only as strong as the data flowing into it. Thank you to Michael Hollan and Pharmaceutical Executive for the thoughtful conversation. Hear Rick’s full perspective on FDA’s pilot program and the future of real-time clinical trial data: https://lnkd.in/e7GuMYHB

Proud of our own Jim Wahl for lending his leadership to Blood Cancer United’s Light The Night Executive Challenge. A meaningful way to mark #ClinicalTrialsDay.

Continued progress in clinical trial modernization requires consistency through change. Following Dr. Marty Makary’s resignation as FDA Commissioner, European Pharmaceutical Review included perspective from our Co-Founder and Chairman, Richard Graham, PhD, on what this moment means for the future of clinical trials. Rick emphasized the importance of sustaining regulatory progress through leadership transitions, while also pointing to a broader opportunity: strengthening how trials are designed, conducted, and monitored before data ever reaches submission. For sponsors, that means staying focused on the part they can control — the quality, integrity, and speed of their own clinical trial execution. Thank you to Catherine Eckford (European Pharmaceutical Review) and European Pharmaceutical Review for including Rick’s perspective. Read the full story: https://lnkd.in/eYNpY6wQ

Clinical trials are becoming more digital. But more technology does not automatically mean better data. Next week, Michael van Miert and Abi Balmer will be in London for the Clinical Trials Technology Congress, joining conversations on how technology can support stronger trial design, execution, and data strategy. At TruTechnologies, we’re focused on one critical piece of that equation: helping sponsors see how trial activities are executed and captured at the source, so they can have greater confidence in the data their studies depend on. If you’ll be there, we’d love to connect. #CTTCongress

TruTechnologies is proud to return as the Presenting Sponsor of the Gold Lantern: United in Remembrance at this year’s Triangle Light The Night! The gold lantern is a powerful symbol of the evening, honoring and remembering those we have lost to cancer. Each lantern carried through the night is a tribute to loved ones and a moment of reflection for families, friends, and the broader community. At TruTechnologies, our work is rooted in a simple belief: patients can’t wait. We’re grateful for this opportunity to once again stand with Blood Cancer United and work toward a future of more hope, more time, and more memories for patients and families. Please join us at Koka Booth Amphitheatre on Saturday, October 17. #TriangleLightTheNight #GoldLantern #UnitedInRemembrance #EndCancer

On site at #OCTEastCoast and ready for a full day of conversations with clinical trial leaders. If you’re thinking about sponsor oversight, site visibility, or how to catch execution issues earlier, stop by and meet the TruTechnologies team. Outsourcing in Clinical Trials Event Series 🌊Kyle Brown Doug Blanchard III Bryce Lugar

Sponsors can’t oversee what they can’t see. That’s why we’re heading to #OCTEastCoast next week to talk about making site activity visible while there’s still time to act. If you’ll be in New Brunswick, we’d love to connect. Outsourcing in Clinical Trials Event Series Bryce Lugar Doug Blanchard III 🌊Kyle Brown

The FDA is moving toward real-time clinical trial data review. It sounds like a clear step forward. But it also raises a bigger question: What does it actually take to trust the data you’re seeing—while a trial is still running? There’s a gap here that doesn’t go away just because review happens sooner. 👇 #ClinicalTrials #DrugDevelopment #ClinicalOperations #DataIntegrity

Day 2 in Burlingame. A lot of great conversations around trial execution, what’s planned versus what actually happens at sites, and how teams are closing that gap. Not a bad crew to spend the week with, either. We’d love to see you at Booth 14 if you’re here. #CTOWestCoast #ClinicalTrials #Oncology #TeamTruTechnologies Clinical Trials in Oncology Event Series Peyton Moser Jason D. Oberholtzer Kate C. Samantha Nelms

We’re heading to Burlingame next week for Clinical Trials in Oncology West Coast. As oncology trials become more complex, the gap between what’s planned and what actually happens in execution only gets wider. That gap is where risk lives. We’ll be onsite talking with sponsors about how to get closer to the source—so they can see what’s happening, when it happens, and catch issues before they impact timelines or data quality. Let us know if you’ll be there. #CTOWestCoast #Oncology #ClinicalTrials Arena International Events Group Clinical Trials in Oncology Event Series Kate C. Peyton Moser Samantha Nelms Jason D. Oberholtzer